Impact of radiotherapy on survival in resected or unresectable anaplastic thyroid carcinomas, a rare cancer network study

Abstract

Purpose. - Anaplastic thyroid carcinomas (ATC) are a heterogenous group of tumors of overall dismal prog-nosis. We designed models to identify relevant prognostic factors of survival of irradiated ATC patients including radiotherapy modalities (field size, dose). Material and methods. - Between 2000 and 2017, 166 ATC patients' treatments were divided into surgery and postoperative radiotherapy (poRT) or definitive radiotherapy (RT). Multiple imputation approach was used for missing data. Prognostic factors were identified using Lasso-penalized Cox modelling and predicted risk scores were built. Results. - Patients undergoing RT (n = 70) had more adverse patient and disease characteristics than those undergoing poRT (n = 96). Corresponding median survival rates were 5.4 and 12.1 months, respectively. PoRT patients undergoing poRT more likely received extended-field radiotherapy with prophylactic nodal irradiation, but rather received platinum-vs. adriamycin-based chemoradiotherapy. Radiotherapy was conventionally fractionated, delivered > 60 Gy in 51.9% and 61.7% and used extended fields in 88.5% and 71.2% of patients with poRT or RT. Radiotherapy interruption rates for toxicity were similar in the two groups. The best poRT-group model identified age > 45yo, PS & GE; 1, pathologic tumor stage & GE; pT4b, > N1 and R2 resection as poor prognostic factors. The best RT-group model (C-index of 0.72) identified PS & GE; 3, > N1 and extended-field radiotherapy with prophylactic nodal irradiation (as opposed to tumour-bed irradi-ation only) as poor prognostic factors. C O N C L U S I O N In patients undergoing poRT, radiotherapy parameters had little influence over their survival irrespective of patient, disease characteristics, and quality of resection. In patients undergoing RT, extended-field radiotherapy improved survival in addition to PS and nodal stage.(c) 2022 Published by Elsevier Masson SAS on behalf of Societe franc , aise de radiotherapie oncologique (SFRO).